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Abstract
Genome-wide association studies (GWAS) have identified 52 independent variants at 34 genetic loci that are associated with
age-related macular degeneration (AMD), the most common cause of incurable vision loss in the elderly worldwide.
However, causal genes at the majority of these loci remain unknown. In this study, we performed whole exome sequencing
of 264 individuals from 63 multiplex families with AMD and analyzed the data for rare protein-altering variants in candidate
target genes at AMD-associated loci. Rare coding variants were identified in the CFH, PUS7, RXFP2, PHF12 and TACC2 genes in
three or more families. In addition, we detected rare coding variants in the C9, SPEF2 and BCAR1 genes, which were
previously suggested as likely causative genes at respective AMD susceptibility loci. Identification of rare variants in the CFH
and C9 genes in our study validated previous reports of rare variants in complement pathway genes in AMD. We then
extended our exome-wide analysis and identified rare protein-altering variants in 13 genes outside the AMD-GWAS loci in
three or more families. Two of these genes, SCN10A and KIR2DL4, are of interest because variants in these genes also showed
association with AMD in case-control cohorts, albeit not at the level of genome-wide significance. Our study presents the
first large-scale, exome-wide analysis of rare variants in AMD. Further independent replications and molecular investigation
of candidate target genes, reported here, would assist in gaining novel insights into mechanisms underlying AMD
pathogenesis.
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Introduction
The genetic basis of common diseases continues to be a subject
of significant interest in human genetics research in the post-
genome era. Genome-wide association studies (GWAS) have
been successful in uncovering hundreds of common genetic
variants associated with multiple complex traits (1). Despite
representing a major advance in deciphering genetic structure
of complex diseases, GWAS have faced two major setbacks.
First, the associated variants often reside in non-coding regions
of the genome, representing a tag SNP (single nucleotide
polymorphism) for the causal variant(s). Thus, the causal gene(s)
and genetic variant(s) are not immediately evident for a majority
of identified loci. Second, barring few exceptions, the associated
variants identified by GWAS explain only a small proportion of
the disease heritability (2). These observations have led to shifts
in paradigms including possible involvement of rare variants
in complex traits. In fact, both common and rare variants have
been recognized to contribute to the genetic architecture of
multifactorial diseases (3). Nevertheless, common variants have
long been central to these investigations, primarily because of
the identification of millions of SNPs across the genome that
could be genotyped in a high-throughput manner (4,5). The
advent of next-generation sequencing technologies and reduced
cost of sequencing have prompted a new wave of studies for
evaluating the impact of rare and low-frequency variants in
complex diseases (6).
Age-related macular degeneration (AMD; MIM, 603075)
is a late-onset multifactorial, neurodegenerative disease,
which affects the macular region of the retina, eventually
resulting in the loss of central vision. AMD afflicts 8.7% of
the worldwide population (7) with over 10 million individuals
in the United States alone, posing a substantial healthcare
burden (8). The clinical presentation of the disease is progressive
and can be broadly divided into early, intermediate and late
(advanced) stage (9). Early and intermediate stages are mostly
asymptomatic and characterized by changes in the retinal
pigment epithelium (RPE) and accumulation of extracellular
aggregates, called drusen. Central vision loss characterizes the
advanced stage, which can be further subdivided into two forms:
geographic atrophy (GA) and choroidal neovascularization (CNV)
(10). Therapeutic interventions are available for many patients
with CNV, which represents a small proportion of all AMD
cases (11).
AMD is a complex trait determined by a combination of
advanced age, genetic variants and environmental factors such
as smoking and nutrition (12,13). Genetic studies in AMD have
contributed significantly to biological underpinnings of its
pathogenesis (14,15). The most recent GWAS of 16,144 patients
and 17,832 control individuals identified 52 independently
associated variants at 34 loci that explain over 50% of the
genomic heritability (16). These findings have highlighted
the complement system, extracellular matrix remodeling and
lipid metabolism in AMD pathogenesis. Rare variants are also
suggested to contribute to the heritability in AMD (16,17).
Targeted sequencing of candidate genes and whole exome
sequencing (WES) have identified rare coding variants in the
CFH, C3, CFI, C9, CFB and COL8A1 genes at GWAS loci (18–24).
Additional studies have established an unequivocal role of the
complement system in AMD pathology (25–30). At this stage, the
contribution of rare variants outside of the GWAS loci remains
largely unexplored due to power issues, as case-control designs
require sequencing of large numbers of samples to achieve
statistical significance.
Early investigations indicating the aggregation of AMD in
families strongly indicated a strong genetic contribution (31–34),
and such families can serve as a reference for identifying rare
variants and causal genes. Linkage analysis in AMD families had
initially led to the identification of the 1q31 and 10q26 loci (35–
38), which were later identified as the top two association signals
in GWAS and/or by candidate gene association at the CFH (39–43)
and ARMS2-HTRA1 (44–46) loci, respectively. In addition, exome
sequencing in large, multiplex families identified a rare variant
in the FBN2 gene (47) in the early form of macular degeneration
and confirmed the occurrence of rare variants in the CFH, CFI,
C9 and C3 genes at multiple AMD loci (21,28,29,48–52). Thus,
AMD families can provide new insights into AMD by identifying
additional rare variants and pointing to candidate causal genes.
In this study, we performed WES of 264 individuals from 63
multiplex families. To determine causality of genes in loci previ-
ously identified by GWAS, we analyzed these families for rare
protein-altering variants in coding regions at AMD-associated
loci. In addition, we examined whole exome data for rare coding
variants outside the AMD-associated loci to identify new AMD
candidate genes.
Results
Whole exome sequencing in AMD families
We assembled a cohort of 226 affected and 38 unaffected individ-
uals from 63 multiplex families with a history of AMD (Table 1). A
majority of the cohort (51.5%) had advanced stages of the disease
(GA, CNV or GA + CNV) with a mean age of 78.2 years. Individuals
with early and intermediate stages had a mean age of 69.1 years
and constituted 34% of the affected individuals (Table 1). We also
included 38 unaffected members (age > 55 years) from 32 fami-
lies with a mean age of 72.1 years. Exome capture and sequenc-
ing was performed at two different centers [at the National Eye
Institute (NEI) for the NEI families and at ErasmusMC Rotterdam
for the Radboudumc families] (Fig. 1). As the WES data were
captured on different platforms, we extracted variants from
the shared 58.55 Mb exome regions. WES data were analyzed
following the guidelines of GATK best practices (Fig. 1), resulting
in the identification of 107,348 coding variants (53). We identified
4957 variants after additional, multi-tiered filtering based on
quality, allele depth, minor allele frequency (MAF) in matched
controls and predicted effect of the variants (Fig. 1). The variants
segregating in a family were considered only if the variant was
shared among 80% or more affected family members and/or
segregated in all but one affected individual. We excluded the
variants that were present in available unaffected member(s) of
the respective family.
Survey of rare coding variants in genes
within GWAS loci
We first analyzed the families for rare (MAF < 1%) coding vari-
ants within 34 AMD-associated loci (Table 2). The locus regions
were defined by genome-wide significant variants and those
within linkage disequilibrium (LD) (r2 > 0.5), with an additional
500 kb to both sides, as described in the most recent AMD-GWAS
study (16). We identified 91 rare variants in 78 genes within
the LD intervals of 29 known AMD loci and initially focused on
loci where rare coding variants were identified in three or more
families. Variants were detected in the CFH, PUS7, RXFP2 and
PHF12 genes in three families and in the TACC2 gene in four
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Table 1. Overview of families analyzed
Radboudumc cohort NEI cohort
Number of families 44 19
Total number of individuals 195 69
Males, females 73,122 30, 39
Number of individuals with advanced AMD 82 54
Mean age for advanced AMD 76.5 80.8
Number of individuals with early or
intermediate AMD
82 8
Mean age for early or intermediate AMD 68.5 74.8
Number of unaffected individuals 31 7
Mean age of unaffected individuals 70.8 77.5
Figure 1. An overview of stepwise filtering of variants identified in multiplex
AMD families using whole exome sequencing. We retained variants that were
shared among 80% or more affected family members or segregated in all but one
affected individual. Variants were discarded if they were present in one or more
unaffected family members.
were predicted as most likely candidates using the gene priority
score (GPS), as described previously (16). The scoring was based
on expression of genes in AMD-relevant tissues (retina, RPE and
choroid) and the presence of rare variants in AMD patients and
their known biological functions. By combining our WES results
with GPS score, we identified three additional likely AMD genes:
SPEF2 (PRLR-SPEF2 locus), BCAR1 (CTRB2-CTRB1 locus) and C9
(C9 locus) (Table 2). Two independent non-synonymous variants
(R201G and R421H) in SPEF2 were predicted to be pathogenic
and identified in two families (Fig. 2G). No additional segregat-
ing rare variants were uncovered among the 16 genes within
the LD region of the PRLR-SPEF2 locus. A non-synonymous and
splice variant in BCAR1 is segregated in two families (Fig. 2H). In
addition, a single family with four affected members revealed
the segregation of a rare, likely pathogenic variant P167S in C9
(Fig. 2D).
We next analyzed the expression of the eight genes where
rare variants were identified in the retinal transcriptome and
expression quantitative trait loci (eQTL) dataset that included
both control and AMD donor samples (54) (Fig. 3). Six of
these genes (CFH, PUS7, PHF12, TACC2, SPEF2 and BCAR1) were
expressed in the retina (counts per million, CPM > 0), while
no retinal expression was detected for RXPF2 and C9 (Fig. 3A).
Additionally, we evaluated gene expression changes during
AMD progression by comparing the gene expression profile
of the control retina with the profiles of the retina during
early, intermediate and late stages of the disease. While we
did not observe a significant difference [at false discovery rate
(FDR) ≤ 10%] during disease progression, several candidates
showed a trend of either increased or decreased expression
(Fig. 3B). We note that expression of four of the candidates (PUS7,
PHF12, SPEF2, BCAR1) is regulated in the retina through common
eQTL variants (Fig. 3C).
Exome-wide analysis of rare pathogenic variants
We then extended our analysis in search of rare pathogenic
variants in genes outside the GWAS loci. We selected genes
with rare (MAF < 1%) variants that were detected in at least
three families and applied an additional predictive causality
filter to focus on the 1% most deleterious variants in the human
genome (CADD score ≥ 20). We also removed the variants that
did not pass the quality score filter in Exome Aggregation Con-
sortium (ExAC) database. Our analyses resulted in the identifi-
cation of 13 candidate genes with 38 rare variants segregating in
three or more families (Table 3). As large or polymorphic genes
harbor a large number of variants, we further prioritized the
list based on the following criteria: (i) whether the gene was
expressed in the human retina (CPM > 0) and is regulated by
an eQTL, (ii) whether common variants around the candidate
gene exhibited a suggestive association (P-value < 5 × 10−4) for
AMD and (iii) whether the candidate gene or a closely related
gene was shown to have a function relevant to AMD pathology.
Ten candidate genes demonstrated expression in the human
retina with a few showing changes during AMD progression
(Fig. 4A and B). Five of the genes also had an eQTL in the retina
(Fig. 4C). One candidate, SCN10A, showed a modest association
(3:38800182_C/T; P-value: 9.63 × 10−5) in the AMD-GWAS (Fig. 4D).
We identified three different rare variants in SCN10A, one non-
sense variant (Q923X) and two non-synonymous variants (P893L
and P332L) in three independent AMD families (Fig. 5A). A rare
frameshift variant (S267fs) in KIR2DL4 is segregated in three
families (Fig. 5B). Based on their role in mitochondrial biogenesis,
ESRRA and VPS13B, each with rare variants in three different
families, could be presented as additional interesting candidates
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Table 2. Rare coding variants (MAF < 1%) in genes within GWAS loci identified by WES
Locus (agenes within
LD ± 500 kb)




Genes with rare variants in three or more families















KMT2E/SRPK2 (8) PUS7 AMD930 7:105148683 rs139058270 0.006 NM_001318163:




PUS7 AMD479 7:105148683 rs139058270 0.006 NM_001318163:



























































Genes with highest GPSa




















BCAR1 W11–4044 16:75286131 rs74024754 0.0029 NM_001170720:
exon2:c.12 + 2 T > C
Splicing —
aGPS refers to gene priority score as described in Fritsche et al. (16), which was a scoring-based method for suggesting most likely candidate at known AMD loci based
on expression, presence of rare variants and known biological function that were deemed important for AMD. Minor allele frequency (MAF) was from non-Finnish
Europeans from ExAC database.
Given that segregation of rare variants in small families can
be detected by chance, we performed simulation analysis to
test the null case of no variant effect on disease by randomly
assigning alleles to subjects in our study and then calculating the
probability of observing segregation in three or more families.
We applied the segregation criteria similar to the criteria that
were used to identify variants in the AMD families and per-
formed 100 000 gene-level simulations for two different variant
sets: one with rare variants identified at the AMD loci and the
other with exome-wide, rare variants after filtering by CADD
score. We observed an average gene-level type I error rate of
7.7 × 10−7 for the AMD loci analysis and 1.87 × 10−7 for the CADD
score filtered exome-wide analysis. The study-level type I error
was 4.6 x 10−4 (AMD loci) and 2.2 × 10−4 (exome-wide). Given
the pedigree structure and variants identified in our study, it is
therefore unlikely to detect segregation of rare variants in three
or more families by chance.
Rare variant association in case-control cohort
We further tested whether candidate genes identified in this
study exhibit rare variant associations in AMD case-control stud-
ies that employed WES or whole genome sequencing (WGS) to
genotype rare variants in coding regions of the genome. We
analyzed the burden of rare coding variants in the eight genes
within GWAS loci (Table 2) and 13 genes identified in our exome-
wide analysis (Table 3) in two different cohorts (see Methods)
(24,30). A meta-analysis of rare variants in 3519 AMD subjects
and 3754 controls suggested a burden of rare variants in the C9
(P = 0.024) and KIR2DL4 (P = 0.035) genes using the burden and
variable threshold (VT) tests (Supplementary Material, Table S1).
Discussion
GWAS and deep sequencing efforts have strongly supported a
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Figure 2. Segregation of rare variants in genes residing within AMD-associated loci. Filled symbols represent the individuals with AMD.
addition to conferring high risk for AMD, rare variant studies can
provide important insights into the phenotypic characteristics
of the carrier patients (55,56). The most recent GWAS examined
both common and rare variants in a large cohort but was limited
to the analyses of known rare variants that were present on
the chip (16) and did not allow sequencing-based discovery of
rare variants. A few sequencing studies attempted to harness
the power of familial cases, but their search was restricted to
known AMD loci (28,49). Here, we present the first, large-scale,
genome-wide survey of rare coding variants in multiplex AMD
families that identified several novel candidate genes/variants
contributing to AMD susceptibility.
Within known AMD susceptibility regions, we identified rare
variants at eight loci; two of these in CFH and C9 have previously
been reported in case-control and familial studies (18,20). These
findings further strengthen the role of the complement pathway
in AMD and validate the presence of highly penetrant, functional
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Figure 3. (A) Mean expression of candidate genes within AMD-associated loci in human donor retina. (B) Heatmap showing the fold change differences observed in
genes during early-, intermediate- and late-stage AMD compared to normal retina. None of the candidate reaches statistical significance of FDR ≤ 10%. (C) Violin plots
showing the relationship between the variant and the gene of an observed eQTL. Fewer individuals with homozygous genotypes of PUS7 (G/G) and SPEF2 (T/T) resulted
in single point in violin plots. P-values for the eVariants: (rs170690–3.97 × 10−5), (7:105733118–1.39 × 10−5), (rs117886541–1.12 × 10−5), (rs78996920–3.85 × 10−10),
(rs12520223–1.75 × 10−8), (rs150308036–3.15 × 10–7), (rs8064132–2.04 × 10−5).
the causal genes at other AMD loci. PUS7 encodes a key RNA-
modifying enzyme. RXFP2 encodes a receptor for glycoprotein
hormones that contains a unique low-density lipoprotein type
A (LDLa) module (57); though this gene is not expressed in the
adult human retina (54), its homolog in zebrafish is transcribed
in the developing brain and retina (58). PHF12 encodes a member
of the PHD zinc finger family of proteins involved in regulation of
ribosomal biogenesis and senescence (59) and could contribute
to AMD pathology through activation of senescence. Although
present in only two families, the findings of rare variants in
SPEF2 and BCAR1 are also noteworthy as both of these candidates
were highlighted as most likely candidate at the AMD-GWAS loci
based on a gene priority score (16). SPEF2 is highly expressed in
the human retina and shows a slight increase in advanced stages
of AMD. SPEF2 is a cilia-related protein and its absence causes
male infertility and primary ciliary dyskinesia (60). This protein
is shown to interact with IFT-related protein, IFT20 (61) that is
required for opsin trafficking and photoreceptor outer segment
development (62). BCAR1 encodes a Src family kinase substrate
that is shown to be involved in early retinal development, and
a mouse model of Bcar1 exhibits dramatic disruption of the
ganglion cell layer (63). Recently, BCAR1 was also identified as a
putative causal gene at the CTRB2/CTRB1 locus by co-localization
of GWAS and single-cell eQTL data (64).
Our survey of candidate genes harboring rare variants outside
AMD loci was aimed at identifying potential novel candidate
genes underlying AMD pathology. Such candidates could have
been missed in GWAS and other association studies if the gene
confers the risk to AMD solely through rare variants, or if the
effect size of the common risk variant is very low, warranting
larger numbers of cases and controls to detect such associations.
We identified 13 candidate genes that harbor rare variants in
more than three families and show, by simulation studies, that
the probability of these variants segregating by chance is very
low. Thus, these genes represent reasonable candidates for AMD
susceptibility. We propose SCN10A and KIR2DL4 as the most
interesting AMD candidates. Common variants at the SCN10A
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Table 3. Candidates with rare coding variants (MAF < 1%) segregating in three or more families identified in exome-wide analysis
Gene Chr: Pos rs Id No. of family MAF_NFE Exonic function Nucleotide change Amino acid
change
CADD_phred
CTDSP2 chr12: 58220816 rs76940645 11 0 Non-synonymous NM_005730:
exon4:c.317 T > C
I106T 25.3
TTN chr2: 179395813 rs55865284 7 0.0001 Non-synonymous NM_003319:
exon186:c.78334G > A
V26112M 22.1
chr2: 179482937 rs72677232 0.0026 Non-synonymous NM_003319:
exon80:c.20053G > A
V6685I 21.6
chr2: 179482994 rs72677231 0.0035 Non-synonymous NM_003319:
exon80:c.19996C > T
R6666C 22.2
chr2: 179486037 rs72677225 0.0065 Non-synonymous NM_003319:
exon74:c.18213G > T
K6071N 22.3
chr2: 179486223 rs17354992 0.0079 Non-synonymous NM_003319:
exon73:c.18133G > A
D6045N 23.2
chr2: 179486345 rs114331773 0.0015 Non-synonymous NM_003319:
exon73:c.18011A > T
E6004V 22.8
chr2: 179537200 rs202014478 0.006 Non-synonymous NM_133378:
exon149:c.30961G > A
V10321I 21.5
chr2: 179549407 rs72650031 0.0077 Non-synonymous NM_133378:
exon128:c.28892C > T
P9631L 20.1
chr2: 179582913 rs72648981 0.003 Non-synonymous NM_133378:
exon83:c.21088G > A
E7030K 22.7
chr2: 179585312 rs17452588 0.008 Non-synonymous NM_133378:
exon77:c.19445C > T
S6482L 22.5
chr2: 179588622 rs201394117 0.0007 Non-synonymous NM_133378:
exon70:c.17632G > A
A5878T 23.6
KIR3DL3 chr19: 55237616 rs143765860 4 NA Non-synonymous NM_153443:
exon3:c.168C > A
N56K NA
chr19: 55246731 rs602444 NA Non-synonymous NM_153443:
exon6:c.961C > T
H321Y NA
DCHS2 chr4: 155156598 rs149548848 4 0.002 Non-synonymous NM_017639:
exon25:c.7841C > T
P2614L 24.9
chr4: 155411721 rs199621086 0.0042 Non-synonymous NM_001142552:
exon1:c.787C > T
R263W 25.9
chr4: 155411948 rs184619033 0.0074 Non-synonymous NM_001142552:
exon1:c.560G > T
R187L 24.2
DNAH14 chr1: 225340410 rs17578819 4 0.0094 Non-synonymous NM_001373:
exon32:c.4970G > A
G1657E 21.8
chr1: 225490915 rs140066130 0.0042 Non-synonymous NM_001373:
exon55:c.8410C > T
R2804C 34
chr1: 225528175 rs184094753 0.0034 Stopgain NM_001373:
exon67:c.10171G > T
E3391X 58
SCN10A chr3: 38768123 — 3 0 Stopgain NM_001293307:
exon15:c.2767C > T
Q923X 24.9
chr3: 38768212 rs138413438 0.0014 Non-synonymous NM_001293307:
exon15:c.2678C > T
P893L 24.7
chr3: 38798606 — 0 Non-synonymous NM_001293306:
exon8:c.995C > T
P332L 33
ESRRA chr11: 64083290 rs150848359 3 0.0098 Non-synonymous NM_001282450:
exon7:c.1124G > A
R375Q 22.4
chr11: 64083293 rs201971362 0.0098 Non-synonymous NM_001282450:
exon7:c.1127G > T
R376L 22.1
ADPRHL1 chr13: 114077172 rs145187729 3 0.0084 Non-synonymous NM_138430:
exon7:c.1030G > A
A344T 20.5
chr13: 114107571 rs138029763 0.0076 Non-synonymous NM_138430:
exon1:c.182 T > C
M61T 26.2
KIR2DL4 chr19: 55324674 rs11371265 3 NA frameshift_insertion NM_001080772:
exon6:c.802dupA
S267fs NA
PLB1 chr2: 28805359 rs144737372 3 0.0013 Non-synonymous NM_001170585:
exon24:c.1687A > G
R563G 22.3
chr2: 28854972 rs74701215 NA Non-synonymous NM_001170585:
exon54:c.3934C > A
P1312T 28.1
TAF1C chr16: 84212875 rs199976567 3 0.0037 Non-synonymous NM_001243158:
exon11:c.1286C > T
S429L 31
chr16: 84213651 - NA Non-synonymous NM_001243158:
exon10:c.604C > A
Q202K 23.3
chr16: 84215010 - 0 Non-synonymous NM_001243158:
exon7:c.170G > A
R57H 34
UNC80 chr2: 210683829 rs200473652 3 0.0019 Non-synonymous NM_032504:
exon12:c.1806G > C
Q602H 23.1
chr2: 210707144 rs78912192 0.0003 Non-synonymous NM_032504:
exon21:c.3434A > C
E1145A 27.9
chr2: 210860221 rs199783352 0.0005 Non-synonymous NM_182587:
exon63:c.9607G > A
E3203K 23.4
VPS13B chr8: 100147957 rs143205296 3 0.0005 Non-synonymous NM_015243:
exon11:c.1559A > G
H520R 24.8
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Figure 4. (A) Mean expression of the candidate genes with rare variants (MAF < 1%) in three or more families that are located outside of AMD-associated loci. (B)
Heatmap showing the fold change differences observed in genes during early-, intermediate- and late-stage AMD compared to normal retina. (C) Violin plots showing
the relationship between the variant and the gene of an eQTL. Fewer individuals with homozygous genotypes of TTN (G/G) resulted in single point in the violin plot.
P-values for the eVariants: (rs66773470–2.66 × 10−6), (rs2278043–5.92 × 10−60), (rs35615286–4 × 10−5), (rs58805123–2.50 × 10−5), (rs11889787–4.11 × 10−5), (rs1800792–
1.56 × 10−5). (D) LocusZoom plot (80) showing the association signals around SCN10A in most recent GWAS analysis in AMD (16).
(16) though not at the level of genome-wide significance, and a
suggestive burden of rare variants in KIR2DL4 has been detected
in a meta-analysis of WGS data in a case-control cohort com-
posed of 3519 cases and 3754 controls (65). SCN10A is a voltage-
gated sodium channel expressed in starburst amacrine cells and
a subset of retinal ganglion cells (66), which is likely the reason
for not observing its expression in the human retina. Gain-
of-function mutations in this gene cause axonal degeneration
leading to painful neuropathy (67). Several retinal diseases are
caused by ion channel mutations including inherited macular
degeneration (68). KIR2DL4, a member of the human killer cell Ig-
like receptor (KIR) family, is expressed primarily in natural killer
(NK) cells and plays an important role in innate immunity (69).
NK cells interact with HLA class ligand through their KIR recep-
tors and a certain combination of HLA-C, and KIR gene variants
have been associated with AMD (70). ESRRA, an estrogen-related
receptor is a key regulator of energy homeostasis and mito-
chondrial function. ESRRA-null mice show altered regulation
of enzymes involved in lipid, eicosanoid and steroid synthesis
(71). Dysfunction in lipid metabolism has been linked to AMD
pathogenesis (72), making ESRRA an attractive candidate for
further investigation. VPS13B is a transmembrane protein with
a function in vesicle-mediated transport. Mutations in this gene
cause Cohen syndrome, whose clinical features include non-
progressive psychomotor retardation, microcephaly and retinal
dystrophy (73).
Our study demonstrates that WES in extended families could
prove valuable for identifying rare coding risk variants in poten-
tially novel AMD genes. Similar results could be obtained from
traditional case-control studies; however, that would require
study designs involving much larger cohorts. A further incor-
poration of expression data from a large cohort of normal and
AMD donors (54) also uncovered new insights. These candidates
do not reach statistical threshold (FDR ≤ 10%) in the differential
expression analysis because of the clinical and genetic hetero-
geneity among AMD and normal individuals and limited power
of the study to detect such differences. Investigation of larger
cohorts as well as other AMD-relevant tissues such as RPE and
choroid will be useful as additional line of evidence in validating
these candidates as AMD-causing genes.
In conclusion, our family-based exome sequencing studies
identified rare coding variants for novel candidate genes at
eight known GWAS loci and 13 additional candidates outside
GWAS regions. Further independent replications and molecular
investigations of the candidate genes and variants, reported




The study population consisted of 264 samples from 63 mul-
tiplex AMD families is collected at two different centers. The
Radboudumc cohort (Fig. 1, Table 1) comprised of 44 families (195
subjects). All patients gave written consent and the local ethics
committees on research involving human subjects approved the
study. Family ascertainment and disease classification for NEI
cohort have been described in detail elsewhere (16,37). Briefly,
samples were ascertained from the clinical practice at the Kel-
logg Eye Center. Fundus photographs, fluorescein angiograms
and eye examinations records were obtained for all probands
and family members and were updated every 1–2 years. The
recruitment and research protocols were reviewed and approved
by the University of Michigan institutional review board, and
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Figure 5. Segregation of the rare variants in SCN10A (A), KIR2DL4 (B), ESRRA (C) and VPS13B (D) in AMD families.
Fundus findings in each eye were classified on the basis of a
standardized set of diagnostic criteria established by the Inter-
national Age-Related Maculopathy Epidemiological Study (74).
The Declaration of Helsinki principles was followed for all pro-
cedures. The NEI cohort (Fig. 1, Table 1) consisted of 19 families
(69 subjects) that were collected at the University of Michi-
gan. All patients signed informed consent, and the Institutional
Review Boards of the University of Michigan and the National
Eye Institute approved the study.
Whole exome sequencing
Genomic DNA was extracted from the peripheral blood using
standard methods. Genomic DNA samples were quantified using
the Promega QuantiFluor® dsDNA system (Promega, Madison
WI, USA), according to the manufacturer’s instructions. The NEI
families were subjected to exome sequencing using standard
library preparation protocol with Agilent SureSelect Human All
exon 50 Mb kit (Agilent Technologies, Santa Clara, CA), following
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amplified and converted to clusters using Illumina Cluster Sta-
tion, and single-end 101 bp sequencing was performed on Illu-
mina GAIIx (Illumina, Inc., San Diego, CA). The Nimblegen Seq-
Cap EZ Exome v2.0 44 Mb kit (Roche Nimblegen, Inc., Madison,
WI) was used for performing WES in the Radboudumc families.
Illumina HiSeq2000 sequencer was used to perform paired-end
sequencing, using Illumina TruSeq V3 chemistry (Illumina, Inc.,
San Diego, CA).
Primary bioinformatics analysis
FastQC (available at http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/) was used to confirm quality of sequencing, after
which adapter indexes were removed using Trimmomatic (76).
Mapping was performed on the hg19/GRCh37 human reference
genome sequence build using BWA (77). Aligned reads were pro-
cessed to mark duplicates using Picard (http://picard.sourcefo
rge.net). The Genome Analysis Toolkit (GATK) recommendations
for best practices were applied for variant calling, local realign-
ment, base quality recalibration and variant recalibration (78).
The annotation of variants was performed with ANNOVAR (79).
Overlapping regions between the capture kits were identified
using the mergeBed tools from the bedtools package (80). Alter-
nate allele frequencies of the variants in non-Finnish European
(NFE) populations were obtained from the Exome Aggregation
Consortium, which constituted data from 33,370 individuals.
Variant filtering and prioritization
We removed the variants that did not pass the variant quality
score recalibration (VQSR) filter. We further retained variants
based on read depth (≥ 5×), and at least 20% of the reads were
attributed to the alternate allele. We applied a segregation filter
where we retained variants that were shared among 80% or more
affected family members or segregated in all but one affected
individual. Variants were discarded if they were present in one
or more unaffected family members. We generated a list of rare
variants with MAF < 1% and low-frequency variants based on
allele frequency data from ExAC non-Finnish Europeans (81). The
AMD locus regions were defined by the genome-wide significant
variants and the variants within linkage disequilibrium (LD)
(r2 > 0.5), adding a further 500 kb to both sides, as described in
the most recent AMD-GWAS analysis (16). Finally, the variant-
level data were collapsed into gene-level data by combining all
variants observed in each gene across different families. For
exome-wide analysis, we applied additional filters of predictive
causality (CADD ≥ 20) and retained variants that passed vari-
ant quality score recalibration in the ExAC database. Common
AMD-associated variants from the most recent GWAS (16) were
visualized using LocusZoom (82).
Simulation analysis of rare variant segregation
Simulation analysis was performed to assess type I errors. We
included all the variants that passed quality control, MAF and
functional filters. We did not include the segregation filter in
order to access the probability of genes/variants, segregating
in three or more families. We started with our list of filtered
variants with allele counts from the AMD loci analysis (2862
variant) and the exome-wide analysis (1299 variants) as our
input. For each variant, we simulated the null case by randomly
distributing its minor alleles across the 264 subjects in the study,
with at most one allele per subject. Then, we applied the same
segregation criteria we used in our real data analysis. Briefly, if
any minor allele was assigned to a control subject, the variant
was discarded; otherwise, we evaluated the segregation pattern
of each family and counted properly segregating families as
described above. We repeated this for all variants within each
gene and then identified all segregating families. We performed
100,000 simulations for each gene in two different scenarios: (1)
2862 variants in 600 genes within the known AMD Loci and (2)
1299 variants with a CADD score ≥ 20 in 1176 genes exome-wide.
The study-level type I error was calculated by multiplying the
gene-level type I errors with the number of genes tested.
Expression and eQTL analysis of control
and AMD retina
The transcriptome data of post-mortem human donor retinas
from 453 donors at different stages of AMD and controls were
analyzed for candidate gene prioritization. The donor retina
that were graded for normal and disease status of AMD using
Minnesota Grading System (MGS), with criteria similar to the
Age-Related Eye Disease Study (AREDS). We analyzed 105 MGS1
(normal), 175 MGS2 (early AMD), 112 MGS3 (intermediate AMD)
and 61 MGS4 (advanced AMD) after initial RNA-seq quality
control described elsewhere. The mean age of donors was
80 years (range 55–107). The methods for RNA sequencing, gene
expression quantitation, differential gene expression and eQTL
analysis are described in detail elsewhere (54). Briefly, RSEM
expected counts from 453 samples and 18,053 genes passing
the expression-level filter (≥ 1 CPM in ≥ 10% of samples) were
transformed into TMM-normalized CPM and then converted
into log2 CPM with an offset of 1. Batch effects were estimated
and corrected using the supervised surrogate variable analysis
(supervised sva) method within the bioconductor sva package
in R. The differential expression between MGS 1 controls and
each disease stage was assessed using the limma package in
R. Fold changes between these comparisons were presented
as heatmaps and violin plots using in-house scripts in R. The
eQTL analysis included 17,389 genes and 8,924,684 genotyped
and imputed common variants. The mapping of cis-eQTLs
[as defined by SNP-gene combination within ±1 Mb of the
transcriptional start site (TSS) of each gene] was performed using
QTLtools to identify genetic variants (eVariants) that control
expression of genes (eGenes) at FDR ≤ 0.05.
Rare variant association analysis in AMD
case-control studies
We analyzed two different cohorts for this analysis. The first
cohort was analyzed using whole genome sequencing data in
4787 subjects consisting of 2394 cases and 2393 controls (30,81).
All the cases had advanced AMD (GA or CNV). The second cohort
was analyzed using whole exome sequencing in 1125 cases
and 1361 controls (24). RAREMETAL was used to perform the
meta-analysis of gene-based tests for rare variants (83).
Supplementary material
Supplementary material is available at HMG online.
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